Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Drug repositioning for psychiatric and neurological disorders through a network medicine approach

Full text
Author(s):
Dias, Thomaz Luscher [1] ; Schuch, Viviane [2] ; Baleeiro Beltrao-Braga, Patricia Cristina [3, 4] ; Martins-de-Souza, Daniel [5, 6, 7, 8] ; Brentani, Helena Paula [9, 10] ; Franco, Gloria Regina [1] ; Nakaya, Helder Imoto [2, 4]
Total Authors: 7
Affiliation:
[1] Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Belo Horizonte, MG - Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo - Brazil
[4] Sci Platform Pasteur USP, Sao Paulo - Brazil
[5] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria, Sao Paulo - Brazil
[6] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas - Brazil
[7] Univ Estadual Campinas, Expt Med Res Cluster EMRC, Campinas - Brazil
[8] DOr Inst Reasearch & Educ IDOR, Sao Paulo - Brazil
[9] Natl Inst Dev Psychiat Children & Adolescents INP, Sao Paulo - Brazil
[10] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Psiquiatria, Sao Paulo - Brazil
Total Affiliations: 10
Document type: Journal article
Source: TRANSLATIONAL PSYCHIATRY; v. 10, n. 1 MAY 12 2020.
Web of Science Citations: 0
Abstract

Psychiatric and neurological disorders (PNDs) affect millions worldwide and only a few drugs achieve complete therapeutic success in the treatment of these disorders. Due to the high cost of developing novel drugs, drug repositioning represents a promising alternative method of treatment. In this manuscript, we used a network medicine approach to investigate the molecular characteristics of PNDs and identify novel drug candidates for repositioning. Using IBM Watson for Drug Discovery, a powerful machine learning text-mining application, we built knowledge networks containing connections between PNDs and genes or drugs mentioned in the scientific literature published in the past 50 years. This approach revealed several drugs that target key PND-related genes, which have never been used to treat these disorders to date. We validate our framework by detecting drugs that have been undergoing clinical trial for treating some of the PNDs, but have no published results in their support. Our data provides comprehensive insights into the molecular pathology of PNDs and offers promising drug repositioning candidates for follow-up trials. (AU)

FAPESP's process: 17/25588-1 - From the basic understanding to clinical biomarkers to schizophrenia: a neuroproteomics-centered multidisciplinary study
Grantee:Daniel Martins-de-Souza
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 18/03673-0 - Biochemical effects of cannabinoids on oligodendrocytes: implications for schizophrenia
Grantee:Daniel Martins-de-Souza
Support Opportunities: Regular Research Grants
FAPESP's process: 14/10068-4 - Multi-User Equipment approved in grant 13/08711-3: mass spectrometer waters SYNAPT G2-Si HDMS + nanoACQUITY UPLC
Grantee:Daniel Martins-de-Souza
Support Opportunities: Multi-user Equipment Program
FAPESP's process: 19/00098-7 - Multi-User Equipment approved in grant 2017/25588-1: cromatógrafo Acquity UPLC I-Class
Grantee:Daniel Martins-de-Souza
Support Opportunities: Multi-user Equipment Program
FAPESP's process: 18/16748-8 - INVESTIGATION OF ZIKA VIRUS ACTION IN CENTRAL NERVOUS SYSTEM CELLS: MODELING INFECTION IN HUMAN ASTROCYTES DERIVED FROM INDUCED PLURIPOTENT CELLS
Grantee:Patricia Cristina Baleeiro Beltrão Braga
Support Opportunities: Regular Research Grants